Skip to main content
Contact Us
Subscribe
E-Edition
73°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Allarity Therapeutics, Inc.
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
March 31, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
March 24, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
March 17, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
March 13, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
March 06, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
March 03, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
February 26, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
February 24, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
February 06, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
January 30, 2025
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
November 18, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
November 14, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
October 22, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
October 10, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
October 03, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
September 16, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 13, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)
September 11, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
July 26, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
July 24, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
July 22, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
June 27, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
June 25, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
May 20, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
May 14, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
May 07, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
May 06, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
May 02, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
April 29, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
April 17, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ALLR
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.